March 2016 - The iCMLf awards the 2016 Goldman Prize to Professor Hagop Kantarjian in recognition of his groundbreaking discoveries, including new targeted-therapies that improved prognosis and survival in patients with CML. The annual Goldman Prize awarded in honour of Professor John Goldman, acknowledges outstanding lifetime contributions to the management of patients with CML.

As a clinical-translational researcher, Professor Kantarjian has contributed to significant improvements in the treatment of various leukemias, including the development and testing of first- and second-generation tyrosine kinase inhibitors. He was a key investigator in clinical trials that led to the approval of imatinib as a treatment for CML. “I try to identify leads in the leukemia laboratory research that can be translated into clinical investigations that advance the care and cure in leukemias”, he explains about his approach.

Professor Kantarjian serves as a Professor and Department Chair at the Department of Leukemia, Division of Cancer Medicine, at the University of Texas MD Anderson Cancer Center in Houston, USA where he is also Samsung Distinguished University Chair in Cancer Medicine and Associate Vice President for Global Academic Programs.

Kantarjian earned his bachelor’s and medical degrees from the American University of Beirut (Lebanon) and completed a fellowship at the MD Anderson Cancer Center. He has authored, or co-authored more than 1,000 peer-reviewed medical publications and is a leading expert in the field of chronic and acute leukemia.

Learn more about Professor Kantarjian here